Year: 2023
Type: article
Abstract: In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and repurposed drugs: the 4-month regimen for drug-susceptible TB, and the 6-month bedaquiline–pretomanid–linezolid regimen with or without moxifloxacin for multidrug-resistant/rifampicin-resistant TB. Even if the evidence at the basis of these new regimens is compelling, several questions remain open, particularly concerning linezolid dose finding, the upsurging threat of bedaquiline-resistantMycobacterium tuberculosisand the feasibility of applying these results to the paediatric population. Several ongoing trials may fill the remaining gaps and produce further reliable evidence to address the outstanding questions in TB treatment shortening.
Source: Breathe
Institutions: Vita-Salute San Raffaele University, Jhpiego, Universidade do Porto, Centro Hospitalar de Vila Nova de Gaia, Administração Regional de Saúde do Norte IP, Instituto de Ciências Biomédicas Albel Salazar, Institute of Public Health, University of Porto, Baylor College of Medicine, German Center for Infection Research, Research Center Borstel - Leibniz Lung Center, Texas Children's Hospital, University of Lübeck, University of California, San Francisco
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4387505249